Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Effect of oral calcium carbonate on uterine contractility: a pilot ra… standard therapy · PMID 42480078 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Ineffective uterine contractions contribute to labour dystocia and are a leading indication for primary caesarean deliv… | Journal of obstetrics and gynaecology : the journal of… 2026-08-16 13:21:27 | Source |
| Research on the safety and efficacy of telitacicept in the treatment… Telitacicept · PMID 42290288 | Lupus · Myasthénie · Lupus · Myasthénie | À vérifier | Publication | PubMed | Voir la publication source This study retrospectively evaluated telitacicept in ten pediatric IgA nephropathy patients with proteinuria (24-hour u… | Renal failure 2026-08-16 13:21:27 | Source |
| The effects of asymmetrical versus symmetrical high-flow nasal cannul… standard therapy · PMID 42345563 | Lupus | Thérapie génique | Publication | PubMed | Voir la publication source High-flow nasal cannula (HFNC) is standard therapy for acute hypoxaemic respiratory failure and is increasingly used in… | Pulmonology 2026-08-16 13:21:27 | Source |
| A Case of Cytokine Release Syndrome (CRS) Related to Treatment With L… Tocilizumab · PMID 42571090 | Cancer · Épilepsie · Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by various factors, including infection a… | IJU case reports 2026-08-16 13:21:21 | Source |
| A curious case of generalized pruritus in giant cell arteritis. Tocilizumab · PMID 42569396 | Cancer · Épilepsie · Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | JAAD case reports 2026-08-16 13:21:21 | Source |
| An antibody-conjugated polymer nanoparticle that targets inflammatory… Tocilizumab · PMID 42241929 | Cancer · Épilepsie · Lupus | Remyélinisation indirecte / réparation · Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Abdominal aortic aneurysm (AAA) tends to occur in the lower segment of the abdominal aorta in the elderly population. I… | Biomaterials advances 2026-08-16 13:21:21 | Source |
| Artesunate-loaded bovine serum albumin nanoplatform with metal-polyph… Artesunate · PMID 42540475 | Cancer | Neuroprotection | Publication | PubMed | Voir la publication source Ferroptosis, an iron-dependent programmed cell death process driven by reactive oxygen species (ROS) accumulation, repr… | International journal of pharmaceutics: X 2026-08-16 13:21:19 | Source |
| Artesunate ameliorates experimental autoimmune uveitis by inhibiting… Artesunate · PMID 41674301 | Lupus | Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source To evaluate the efficacy and underlying molecular mechanisms of artesunate (ART) in experimental autoimmune uveitis (EA… | Redox report : communications in free radical research 2026-08-16 13:21:19 | Source |
| Combinations of stem bark powders of Enantia chlorantha and Uvaria ch… Artesunate · PMID 42349770 | Lupus | À vérifier | Publication | PubMed | Voir la publication source The stem bark of Enantia chlorantha Oliver (Annonaceae) and Uvaria chamae P. Beauv (Annonaceae) is widely used in Afric… | Journal of ethnopharmacology 2026-08-16 13:21:19 | Source |
| BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a random… Descartes-08 · PMID 41514038 | Lupus · Myasthénie · Myopathies · Myasthénie · Lupus · Myopathies | Immunomodulation · Traitement symptomatique · Thérapie cellulaire · Thérapie gé… | Publication | PubMed | Voir la publication source Myasthenia gravis (MG) is driven by the secretion of autoantibodies from pathogenic B cell maturation antigen (BCMA)-ex… | Nature medicine 2026-08-16 13:21:14 | Source |
| Male circumcision. Pregnancy and Medically Assisted Conception in Rare Diseases · PMID 22926175 | Cancer | Traitement symptomatique | Publication | PubMed | Voir la publication source Male circumcision consists of the surgical removal of some, or all, of the foreskin (or prepuce) from the penis. It is… | Pediatrics 2026-08-16 13:21:13 | Source |
| CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for th… UCAR-T cells · PMID 40789664 | Lupus | Ralentissement de la progression · Thérapie cellulaire · Thérapie génique | Publication | PubMed | Voir la publication source Autologous chimeric antigen receptor T (CAR-T) cell therapy has demonstrated efficacy in the treatment of acute myeloid… | Chinese medical journal 2026-08-16 13:21:10 | Source |
| A ROS‑responsive liposome for atherosclerosis treatment via combined… Atorvastatin · PMID 42592100 | Lupus | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Atherosclerosis is one of the leading causes of death worldwide. Excessive lipid accumulation and defective efferocytos… | International journal of pharmaceutics: X 2026-08-16 13:21:09 | Source |
| High-throughput signal detection of hepatotoxic drug-drug interaction… Atorvastatin · PMID 42311091 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Elderly patients are highly susceptible to drug-drug interaction (DDI)-induced liver injury, yet comprehensive real-wor… | Annals of medicine 2026-08-16 13:21:09 | Source |
| Jianpi Qutan Formula attenuates vulnerable plaques by regulating IGFB… Atorvastatin · PMID 42302944 | Lupus | Traitement symptomatique · Thérapie cellulaire | Publication | PubMed | Voir la publication source Spleen deficiency phlegm-turbidity syndrome (SD-PTS) is a common traditional Chinese medicine (TCM) pattern in unstable… | Journal of ethnopharmacology 2026-08-16 13:21:09 | Source |
| Metabolic Syndrome and Its Correlates in Systemic Lupus Erythematosus… Assessment of Blood Indices in Systemic Lupus Erythematosus · PMID 41439507 | Lupus | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Metabolic Syndrome (MetS), defined by the International Diabetes Federation, is a constellation of risk factors that el… | Annals of African medicine 2026-08-16 13:21:08 | Source |
| Outcomes of pregnancies complicated by maternal autoimmune diseases i… Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic… | Lupus · Myopathies | Immunomodulation · Thérapie cellulaire · Thérapie génique | Publication | PubMed | Voir la publication source Maternal autoimmune diseases, including Sjögren's disease (SjD), systemic lupus erythematosus (SLE), rheumatoid arthrit… | AJOG global reports 2026-08-16 13:21:07 | Source |
| Colonic Perineurioma Presenting as a Small Subepithelial Lesion With… Anti-CD19-CD3E-CAR-T cells · PMID 42283027 | Lupus | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source A 59-year-old man with a history of colorectal polypectomy underwent a screening colonoscopy. A 5-mm reddish lesion was… | DEN open 2026-08-16 13:21:05 | Source |
| Small-Bowel Impaction Caused by Mechanical Interlocking Between Duode… Anti-CD19-CD3E-CAR-T cells · PMID 42318089 | Cancer | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Duodenal self-expandable metal stents (SEMS) are widely used to treat malignant gastric outlet obstruction (GOO). Howev… | DEN open 2026-08-16 13:21:05 | Source |
| Association between the Presence of Autoantibodies Targeting Ficolin-… Anti-ficolin-3 Autoantibodies in Lupus Nephritis · PMID 27631981 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoanti… | PloS one 2026-08-16 13:21:04 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||